Business Wire

QPS Expands Clinic in Miami, Florida to Accommodate Increasing Demand for Obesity Trials

Share

QPS, a leading global contract research organization (CRO), continues to expand and align its full-service preclinical, bioanalysis, and clinical capabilities with the evolution of demand for clinical trials. Today, QPS announced the expansion of its Miami, Florida Phase I clinical trial capabilities to support the growing needs of sponsors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521634782/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

New, state of the art, clinical trial unit at QPS Miami in South Miami, Florida USA. (Photo: Business Wire)

QPS announces the grand opening of its newest clinical trials unit in Miami, Florida. This new 21 bed unit will complement the existing 85 bed clinical trials unit currently serving the Biotech and Pharmaceutical community. With this new capacity, QPS is poised to accommodate the rapidly increasing demand for obesity trials, as well as continue to support complex, early phase studies in special populations. QPS has extensive experience in allergies, asthma, cell & gene therapy, CNS, COPD, diabetes, elderly, oncology, pediatrics, rheumatoid arthritis, vaccines, women’s health, and many more therapeutic areas.

“We have expanded our Phase I clinical trial capabilities to better serve the hundreds of companies developing potential new obesity-related drugs. We have completed more than 1,500 Phase I-IV clinical trials for drug candidates and this expansion will enable us to support exponentially more sponsors as they progress compounds through proof of concept and First-in-Human trials to the point of candidate nomination,” said Benjamin Chien, Chairman, President, and CEO, QPS Holdings, LLC.

“Our pipeline is filled with sponsors that need this level of support. The number of First-in-Human studies is rapidly increasing and there are very few sites across the country that can conduct them,” said Jose Marcos, Vice President of Clinical Operations, QPS Miami. “QPS is well-known for its success in First-in-Human studies. We excel at complex and special population Phase I trials, and our enrollment and completion rates are among the best in the industry.”

With the expansion comes an increased focus on quality. “To ensure the quality of our clinical trials is maintained, QPS has hired an additional full-time principal investigator to ensure dedicated, physician-involvement at every stage of our trials,” said Chien. “We now have five full-time principal investigators, and a network of more than 25 board-certified subspecialty physician investigators to support the increased volume of studies in our pipeline.”

Wendy Marquina, MD, American Board of Obesity Medicine certified physician, has joined QPS as a primary investigator dedicated to Phase I trials. She brings Board Certification in Obesity, as well as expertise in internal medicine and women’s health to QPS. Since the discovery of the anti-obesity effects of GLP1 and GIP inhibitors, the number of obesity-related clinical trials has dramatically increased. More than 2,300 clinical studies related to obesity are listed as ongoing on clinical trials.gov, and the number is increasing as more companies join the effort to tackle this serious disease and its related comorbidities.

“We expect this demand for obesity-related studies to continue,” said Marquina. “Obesity trials are specialized and unique. And they are in high demand, particularly for companies that want to find an effective solution to this debilitating disease. The road so far is littered with failures in this space, so there is real excitement in the medical community that there may finally be a pathway to help these patients.”

Supporting this expansion in Miami, QPS has co-located its specialty lab services within its Miami-based clinical site. “In the market, you’ll find CROs that offer clinical services, and then you’ll find specialized labs. At QPS, we now we have the unique combination of clinical services and a specialized lab combined under one roof,” said Chien. “That’s important because many of our studies require lab samples to be processed quickly, in less than eight hours. This is only possible by having the clinical site and specialty lab co-located.”

With this newly expanded facility and additional leadership specializing in obesity, QPS is satisfying the need for agility, flexibility, and speed in the global drug development community, with a focus on serving the needs of the Biotech and Pharmaceutical industry to support global drug development from preclinical through post-marketing needs.

ABOUT QPS HOLDINGS, LLC

QPS is a GLP- and GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has grown from a tiny bioanalysis shop to a full-service CRO with 1,200+ employees in the US, Europe and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trials and clinical research operations services. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email infopr@qps.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Gabrielle Pastore, QPS
1-302-635-4290
Gabrielle.Pastore@qps.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution22.7.2024 16:16:00 CEST | Press release

Rapid Medical™, a leading developer of advanced endovascular devices, announces the first procedures in the USA with the breakthrough deflectable access platform DRIVEWIRE 24 at the 2024 Society of NeuroInterventional Surgery’s (SNIS) 21st Annual Meeting. With active technology, DRIVEWIRE articulates a wide range of catheters for direct access to endovascular locations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722355520/en/ DRIVEWIRE 24 redefines interventional access by providing an active deflectable tip that controls and steers a range of catheters directly to the target vessels. Whereas conventional access devices are reactive and rely on external forces to reach their target, DRIVEWIRE's active technology selects turns on-demand and handles the complexity of navigating the vascular highway with ease. (Graphic: Business Wire) “DRIVEWIRE addresses a major unmet need in the endovascular space,” exclaims Dr. Shahra

Cessna Caravan Flight Deck to Feature Cockpit Advancements, Enhancing Flight Experience for Pilots22.7.2024 15:00:00 CEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced significant enhancements to its legendary Cessna Caravan and Cessna Grand Caravan EX utility turboprop aircraft. A brighter, modernized flight deck with new backlit panels, along with other amenities designed to elevate the pilot experience, are the direct result of continuous conversations with customers. The enhancements, which are expected to be available in 2025, will be standard on all new Caravan and Grand Caravan EX aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722286058/en/ Textron Aviation | Cessna Grand Caravan EX & Cessna Caravan (Photo: Business Wire) “The enhancements to the Cessna Caravan flight deck demonstrate our continued commitment to providing the best possible flight experience for our customers,” said Christopher Crow, vice president, Piston and Utility Sales. “Our ongoing investments in this family of aircraft cont

i2c Inc. Announces Strategic Partnership with Beyon Money Business to Launch Corporate Card Program22.7.2024 15:00:00 CEST | Press release

i2c Inc., a leading provider of digital banking and payments solutions, today announced that it is partnering with Beyon Money Business, a new vertical offering digital financial solutions for SMEs and Corporates, to launch an advanced corporate expense card program tailored to the small to mid-size enterprise sectors. The program will be available in Bahrain initially and throughout the states of the Gulf Cooperation Council (GCC) in the future. Leveraging i2c’s modular building block SaaS technology, the Beyon Money Business program underscores its commitment to flexible financial products and to modernizing how corporates manage their expenses through enhanced functionality and security features, such as 3D security for e-commerce transactions. The launch of Beyon Money Business directly responds to the growing need for specialized corporate financial tools. With i2c's flexible banking and payments platform enabling the development of a state-of-the-art expense management solution,

Xsolla Expands Support for Game Developers Through the Greater China Region Launch, Marking a New Era in the Gaming Industry22.7.2024 14:00:00 CEST | Press release

Xsolla, a global video game commerce company known for its extensive suite of tools and services specifically designed for the game industry, is thrilled to announce the grand opening of the Xsolla Greater China Region office. The opening event will occur on Monday, July 22, 2024, at D-06 Parkview Green Fangcaodi, Chaoyang District, signifying a renewed commitment to enhancing and growing the video game industry in China and worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722568214/en/ (Graphic: Xsolla) The expansion of the Xsolla Beijing office embodies a vision to serve as a humble partner and provide access to the tools and services for everyone in the gaming community, assisting companies with ambitions to navigate and reach emerging markets swiftly. This expansion is not just a physical establishment; it is the center of China's technology and gaming community. Under the theme "Equal Access for Everyone," t

TOM FORD Announces the Departure of Creative Director Peter Hawkings22.7.2024 14:00:00 CEST | Press release

TOM FORD announced today that Peter Hawkings is stepping down as Creative Director of the brand. Peter Hawkings has been at TOM FORD since its inception and at the helm of creative since April 2023. “I would like to express my gratitude to Peter for his exceptional contributions to TOM FORD from the very beginning,” said Guillaume Jesel, President and CEO, TOM FORD and Luxury Business Development, The Estée Lauder Companies. "I want to thank Peter for his collaboration since TOM FORD FASHION became part of the Ermenegildo Zegna Group. Along with his team, Peter has contributed to this important initial phase of development. I wish him all the best in his next chapter,” said Lelio Gavazza, CEO of TOM FORD FASHION. The Spring-Summer 2025 collection will be presented in the Milan showroom in September 2024. A successor will be announced in the near future. About TOM FORD TOM FORD IS A GLOBAL DESIGN HOUSE OFFERING EXCEPTIONAL LUXURY WOMEN’S AND MEN’S FASHION, ACCESSORIES, EYEWEAR AND BEAUT

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye